HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Lowers Price Target to $5.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has maintained a Buy rating on Xeris Biopharma Holdings (NASDAQ:XERS) but reduced the price target from $6 to $5.5.

November 13, 2023 | 11:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst maintains a Buy rating on Xeris Biopharma Holdings but lowers the price target to $5.5.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, which could be positive for the stock. However, the reduction in the price target may indicate a tempered expectation for the stock's performance, which could have a neutral to slightly negative impact in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100